Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Registry collecting data and samples from people with sarcoma

Collects clinical, molecular and patient-reported data from people with sarcoma over time.

Plain-language title generated from the registry record
Registry title: The Sarcoma Biology and Outcome Project

Key facts

Where
Heidelberg, GermanySee the site

Where in Germany

  • National Center for Tumour Diseases, University Hospital HeidelbergHeidelberg, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Prof. Dr. Richard F Schlenk
Trial code
NCT04758325
Record updated
25 March 2025
Original description
SarcBOP - An interdisciplinary and translational registryRead full original descriptionShow less

A Prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Adolescent and Adult Patients With Soft-tissue and Bone Sarcoma

SarcBOP - An interdisciplinary and translational registry

SarcBOP aims to establish a database that integrates every aspect possibly relevant to sarcoma treatment and research. SarcBOP thus will not be limited to specific questions or patient groups, but instead will build a comprehensive database including clinical, pathologic, and radiologic information, multi-layered molecular data, and patient-reported outcomes, combined with a dedicated biobank for tissue samples and liquid biopsies. As the study integrates seamlessly with the clinical activities of the Heidelberg Sarcoma Center, the Molecular Diagnostics Program of NCT Heidelberg, including the NCT/DKTK MASTER Program, and with the NCT Trial Center, including the PMO Clinical Trials Program, SarcBOP will generate a comprehensive and continuously growing resource for clinicians, researchers, and, finally, patients.

Inclusion: Suspected or proven diagnosis of soft-tissue or bone sarcoma (STBS); Age ≥12 years; Ability to understand nature and individual consequences of the registry; Written informed consent; Subjects who are physically or mentally capable of giving consent.

Exclusion: Severe neurological or psychiatric disorder interfering with the ability to give written informed consent.

ClinicalTrials.gov NCT04758325